Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study


DOI:
Study Type

Phase III Randomized Trial (MONALEESA-3)

Population

HR+/HER2- Advanced Breast Cancer

Key Outcome

QoL maintained; TTD delayed in Ribociclib arm

Study Design & Arms

Baseline Quality of Life (EORTC QLQ-C30)

Comparison of mean baseline Global Health Status scores (Mean ± SD).

Time to Definitive Deterioration (Median Months)

Median months until ≥10% deterioration in Global Health (M02) and Pain Severity (M03).

Hazard Ratios for Deterioration (Forest Plot)

HR < 1 favors Ribociclib. Error bars represent 95% CI.

Study Population (N)

Randomization 2:1 ratio.

Metric Summary Overview

Key metrics and their primary outcomes.

Appendix: Raw Data & Provenance

Metric Group Value Source
Selected: none

AI edit element

Describe the change you want. Optional: attach an image.
No image attached

Theme

👀 View Mode